Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NCNA by emailGet an email when NCNA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NCNA, unsubscribe in one click. Privacy
📣 What NCNA Says Is Next
in 2026 · “We also anticipate obtaining regulatory guidance from the FDA on our registrational strategy for NUC-7738 in melanoma in 2026.In December 2025, we presented data from the NuTide:701 study at the annual ESMO Immuno-Oncology Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor-based therapy.”
Company press release, May 6, 2026 · SEC filing
in 2026 · “In June 2025, we initiated an expansion of the Phase 2 part of the NuTide:701 study of NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma and we expect to announce data from this NuTide:701 expansion study in 2026.”
Company press release, May 6, 2026 · SEC filing
in 2026 · “Soluble and exosomal pembrolizumab in patients with metastatic melanoma and expect expression of PD-L1 have been implicated in resistance to PD-L1 to report final data from this expansion study in 2026.”
Company press release, May 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NCNA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NCNA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.